Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

November 3, 2017 Using PDX as Surrogate Models for TME Investigation The diversity of cancers is due to the fact that there are numerous different types, along with many different mutations. In previous blogs we have discussed how both heterogeneity and the tumor microenvironment (TME) play a role in tumor progression, metastasis, and resistance, as well as how stromal interactions and the immune microenvironment are ... LEARN MORE
October 31, 2017 How to Choose the Right Type of Mouse Clinical Trial As covered in our recent blog post, Mouse Clinical Trials using patient-derived xenograft (PDX) models provide more ... LEARN MORE
October 26, 2017 Post FDA Approval: CAR-T Therapy Key Facts A few weeks ago, the FDA issued a historic approval of the first cancer cell therapy using a chimeric antigen receptor ... LEARN MORE
October 24, 2017 Top 5 Reasons To Use Mouse Clinical Trials Preclinical oncology drug development needs new tools and approaches. Current methods result in 95% attrition rates for ... LEARN MORE
October 19, 2017 Quick Guide: Top 3 AML Approval Trends for 2017 Acute myeloid leukemia has been the focus of much drug development, but few drug approvals, for the past few decades. ... LEARN MORE
October 17, 2017 The Role of Gut Microbiota and Implications for IBD Over the past 10 years, scientists have discovered that changes in the composition of the gut microbiota play a pivotal ... LEARN MORE
October 12, 2017 Organ-on-a-Chip: The Future of Improved Drug Discovery? I’m a firm believer in the use of animal models in medical research. This is so for many reasons. A chemist and mentor of mine once said “to truly do drug discovery you absolutely need a liver and circulatory system”. LEARN MORE
October 10, 2017 ADA 2017 Video Poster Review Naturally Diabetic NHP Immune Cell Changes Correspond to Human Type 2 Diabetes While changes in immune cell ... LEARN MORE
October 5, 2017 What's Next for Immune Checkpoint Inhibitors: TIM-3? Unlike negative regulators, such as PD-1 and CTLA-4 (which have been proposed as therapeutic targets in different ... LEARN MORE
October 3, 2017 First Stable, Serially Transplantable M5 AML PDX Model Published It is traditionally difficult to develop stable blood cancer patient-derived xenograft (PDX) models. Historically, ... LEARN MORE
September 28, 2017 Impact of Anesthesia During Comprehensive Assessments On Glucose Homeostasis in Diabetic NHPs In the clinic, either an oral glucose (oGTT) or mixed meal (MMTT) tolerance test is used to provide comprehensive assessment of glucose homeostasis in type 2 diabetic (T2D) patients. Similar procedures can also be performed preclinically in animal models. LEARN MORE
September 26, 2017 Epigenetic Inhibitors: Strategies to Enhance Patient Response to Immunotherapy Major breakthroughs in the treatment of patients with multiple types of cancer have been achieved by drugs targeting ... LEARN MORE
September 21, 2017 Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎ A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on ... LEARN MORE
September 19, 2017 Beginners Guide: Humanized Drug Target Immuno-Oncology Models Our recent post compared stable vs transiently humanized models, which are needed when human-specific therapeutics are ... LEARN MORE
September 14, 2017 First Type 2 Diabetes Publication Comparing Pros and Cons of Two Preclinical Continuous Glucose Monitoring Systems Significant Correlation between Blood Glucose Levels Measured by Glucometer and both the Dexcom G4 Platinum and HD-XG ... LEARN MORE